Stay updated on ALD403 Safety, Efficacy, Pharmacokinetics Clinical Trial

Sign up to get notified when there's something new on the ALD403 Safety, Efficacy, Pharmacokinetics Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ALD403 Safety, Efficacy, Pharmacokinetics Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:35:38.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the safety, pharmacokinetics, and efficacy assessment of ALD403 in preventing migraine headaches in frequent episodic migraineurs for 24 weeks.
    Difference
    0.1%
    Check dated 2024-06-06T14:21:38.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the diagnosis and history of migraines, medication usage, and contraceptive requirements, among other factors. Previously, this section only indicated that no information was provided.
    Difference
    29%
    Check dated 2024-05-22T20:56:57.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:48:41.000Z thumbnail image

Stay in the know with updates to ALD403 Safety, Efficacy, Pharmacokinetics Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ALD403 Safety, Efficacy, Pharmacokinetics Clinical Trial page.